The Long-Term Effectiveness of Omalizumab in Adult Patients with Severe Allergic Asthma: Continuous Treatment Versus Boosting Treatment

The implications of boosting Omalizumab treatment (OT) in patients with severe allergic asthma (SAA) remain unclear. The study aimed to explore and compare the 12-month effectiveness between continuous, at least 10-month OT (continuation group) and four-month boost of Omalizumab (boost group) in adult patients with SAA. In this retrospective cohort study, clinical data were collected for further analysis. Of all participants (n = 124), a significant reduction in annual exacerbations (baseline = 0.8 ± 1.5, follow-up = 0.5 ± 1.0, p = 0.047 *) and improvement in small airway ventilation as evaluated by forced expiratory flow at 25–75% (baseline = 55.1 ± 11.1%, follow-up = 59.4 ± 8.4%, p < 0.001 *) were found in the continuation group (n = 110). By contrast, the boost group (n = 14) had significantly increased annual exacerbations (baseline = 0.7 ± 1.4, follow-up = 2.9 ± 3.6, p = 0.031 *) and impaired small airway function (baseline = 55.3 ± 12.9, follow-up = 52.1 ± 12.5, p = 0.026 *). Furthermore, the continuation group rather than the boost group had significant decreases in the frequency of oral corticosteroid (OCS) use as controllers (baseline = 32.7%, follow-up = 20.0%, p = 0.047 *; baseline = 50.0%, follow-up = 21.4%, p = 0.237, respectively) and OCS maintenance dose (mg/month) (baseline = 85.9 ± 180.8, follow-up = 45.8 ± 106.6, p = 0.020 *; baseline = 171.4 ± 221.5, follow-up = 50.0 ± 104.3, p = 0.064, respectively), and increases in asthma control test scores (baseline = 16.0 ± 3.0, follow-up = 19.8 ± 4.4, p < 0.001 *; baseline = 14.6 ± 3.8, follow-up = 19.7 ± 4.7, p = 0.050, respectively). Continuous OT would be beneficial for adult patients with SAA, while boost of Omalizumab would worsen their long-term outcomes.

Download Full-text

Predictors of a Minimal Clinically Important Difference Following Omalizumab Treatment in Adult Patients With Severe Allergic Asthma

Frontiers in Medicine ◽

10.3389/fmed.2021.762318 ◽

2022 ◽

Vol 8 ◽

Author(s):

Wei-Chang Huang ◽

Pin-Kuei Fu ◽

Ming-Cheng Chan ◽

Chun-Shih Chin ◽

Wen-Nan Huang ◽

...

Keyword(s):

Lung Function ◽

Allergic Asthma ◽

Asthma Control ◽

Minimal Clinically Important Difference ◽

Adult Patients ◽

Blood Eosinophil ◽

Asthma Control Test ◽

Cross Sectional ◽

Clinically Important Difference ◽

Severe Allergic Asthma

Several factors have been found to be predictors of a good response following omalizumab treatment in patients with severe allergic asthma (SAA). However, it remains unclear whether clinical characteristics can predict a minimal clinically important difference (MCID) following omalizumab treatment in this population. Therefore, the aim of this study was to investigate the features associated with an MCID following omalizumab treatment in adult patients with SAA. Of the 124 participants enrolled in this retrospective, cross-sectional study, 94, 103, 20 and 53 achieved the MCID following treatment with omalizumab and were considered to be responders of exacerbation reduction (no exacerbation during the 1-year follow-up period or ≧50% reduction in exacerbations from baseline), oral corticosteroid (OCS) sparing (no use of OCS to control asthma during the study period or a reduction of the monthly OCS maintenance dose to <50% of baseline), lung function (an increase of ≧230 ml in the forced expiratory volume in 1 s from baseline) and asthma control (an increase of ≧3 points in the asthma control test score from baseline), respectively. Normal weight [<25 vs. ≧30 kg/m2, odds ratio (OR) = 3.86, p = 0.024] was predictive of a responder of reduction in exacerbations following omalizumab treatment while subjects with a blood eosinophil level of <300 cells/μL (<300 vs. ≧300 cells/μL, OR = 5.81, p = 0.001) were more likely to exhibit an MCID in OCS sparing. No factor was found to be a predictor of lung function or asthma control. When choosing treatment for adult patients with SAA, our findings may help to select those who may benefit the most from omalizumab treatment.

Download Full-text

P096 Long-term follow-up of adolescent and adult patients with cystic fibrosis: a single centre's experience

Journal of Cystic Fibrosis ◽

10.1016/s1569-1993(21)01122-x ◽

2021 ◽

Vol 20 ◽

pp. S68

Author(s):

A.I. Yilmaz ◽

G. Ünal ◽

B.S. Kibar ◽

P. Sevgi ◽

O. Eĝil ◽

...

Keyword(s):

Cystic Fibrosis ◽

Adult Patients ◽

Long Term Follow Up

Download Full-text

Long-term Follow-up in Adult Patients with Cystic Fibrosis and Deep Intronic Splicing Variants

Archivos de Bronconeumología (English Edition) ◽

10.1016/j.arbr.2020.11.017 ◽

2021 ◽

Vol 57 (7) ◽

pp. 501-503

Author(s):

Antonio Álvarez ◽

Karina Loor ◽

Paula Fernández-Alvarez ◽

Silvia Gartner ◽

Eva Polverino ◽

...

Keyword(s):

Cystic Fibrosis ◽

Adult Patients ◽

Splicing Variants ◽

Long Term Follow Up

Download Full-text

Long-term follow-up of dysphagia in adult patients with Duchenne muscular dystrophy

European Journal of Paediatric Neurology ◽

10.1016/j.ejpn.2018.06.004 ◽

2018 ◽

Vol 22 (5) ◽

pp. 786-790 ◽

Cited By ~ 2

Author(s):

Yuka Yamada ◽

Michiyuki Kawakami ◽

Ayako Wada ◽

Shogo Fukui ◽

Koshiro Haruyama ◽

...

Keyword(s):

Duchenne Muscular Dystrophy ◽

Muscular Dystrophy ◽

Adult Patients ◽

Long Term Follow Up

Download Full-text

MO291RITUXIMAB IS EFFECTIVE AND SAFE IN ADULTS WITH STEROID-DEPENDENT NEPHROTIC SYNDROME: A LONG-TERM, SINGLE-CENTER EXPERIENCE

Nephrology Dialysis Transplantation ◽

10.1093/ndt/gfab104.0049 ◽

2021 ◽

Vol 36 (Supplement_1) ◽

Author(s):

Gemma Patella ◽

Alessandro Comi ◽

Giuseppe Coppolino ◽

Nicolino Comi ◽

Giorgio Fuiano ◽

...

Keyword(s):

Nephrotic Syndrome ◽

Case Series ◽

Adult Patients ◽

Single Center ◽

Single Center Experience ◽

Steroid Dependent ◽

The Mean ◽

Steroid Dependent Nephrotic Syndrome

Abstract Background and Aims Steroid-dependent nephrotic syndrome (SDNS) may require a prolonged multi-drug therapy with risk of drug toxicity and renal failure. Rituximab (RTX) treatment has been found to be helpful in reducing the steroid dosage and the need for immunosuppressants (ISs), but little data are currently available regarding very long-term outcomes in adults. We herein describe a long-term, single-center experience of RTX use in a large series of adults with SDNS. Method We studied 23 adult patients with SDNS (mean age 54.2±17.1 y; 65% male; BMI 28.5±4.7), mostly consequent to membranous (47.8%) or focal glomerulonephritis (30.2 %) who were eligible to start a RTX regimen. Before entering the RTX protocol, proteinuria and eGFR were 7.06±3.87 g/24h and 65.9±28.2 ml/min/1.73 m2, respectively; albumin and CD19/CD20 ratio were 2.9±0.9 g/L and 0.99±0.01 respectively; the mean number of ISs was 2.39±0.89 and the mean annual rate of relapses was 2.2±0.9. Results Patients were followed over a mean follow-up of 64 months (range: 12-144). After RTX (mean dose: 1202.1±372.4 mg) the rate of relapses was virtually nullified (p<0.001). eGFR remained roughly stable (62.1±19.8 ml/min/1.73 m2, p=NS), while proteinuria, albumin, CD19/CD20 and BMI all significantly improved (p ranging from 0.01 to 0.001). The mean number of additional ISs was also reduced (0.44±0.12; p<0.001) and RTX enabled discontinuation of steroids in 13/23 (56.5%) patients. No major adverse events related to therapy were recorded. Conclusion Findings from this large case-series with a remarkable very long follow-up reinforce the role of RTX as an efficient and safe weapon to improve outcomes in adult patients suffering from SDNS.

Download Full-text

ANAPHYLACTOID PURPURA (SCHÖNLEIN-HENOCH SYNDROME)

PEDIATRICS ◽

10.1542/peds.16.2.196 ◽

1955 ◽

Vol 16 (2) ◽

pp. 196-206

Author(s):

Ralph J. P. Wedgwood ◽

Marshall H. Klaus

Keyword(s):

Renal Disease ◽

Acute Phase ◽

Chronic Renal Disease ◽

Average Length ◽

Adult Patients ◽

Follow Up Study ◽

Long Term Follow Up

A long-term follow-up study of 26 children with anaphylactoid purpura (Schönlein-Henoch Syndrome) is presented. The average length of follow-up was 4½ years. Of these 26 children, 10 were found to have an apparent latent nephritis characterized by hematuria and cylinduria, but without marked proteinuria. Nine of the ten children were over the age of 6 years at the time of onset of purpura; 6 had proteinuria or hematuria during the acute phase of the disease. It is suggested that this renal sequela of anaphylactoid purpura may constitute one of the origins of chronic renal disease "of unknown etoiology" which occurs in adult patients.

Download Full-text

Long-term follow-up of 103 untreated adult patients with type 1 Gaucher disease

Molecular Genetics and Metabolism ◽

10.1016/j.ymgme.2018.12.108 ◽

2019 ◽

Vol 126 (2) ◽

pp. S49

Author(s):

Tama Dinur ◽

Ari Zimran ◽

Michal Becker Cohen ◽

David Arkadir ◽

Claudia Cozma ◽

...

Keyword(s):

Gaucher Disease ◽

Adult Patients ◽

Long Term Follow Up ◽

Type 1 Gaucher Disease

Download Full-text

Long‐term follow‐up of adult patients with congenital heart disease and an implantable cardioverter defibrillator

Congenital Heart Disease ◽

10.1111/chd.12767 ◽

2019 ◽

Vol 14 (4) ◽

pp. 525-533 ◽

Cited By ~ 2

Author(s):

Madalena Coutinho Cruz ◽

André Viveiros Monteiro ◽

Guilherme Portugal ◽

Sérgio Laranjo ◽

Ana Lousinha ◽

...

Keyword(s):

Congenital Heart Disease ◽

Heart Disease ◽

Implantable Cardioverter Defibrillator ◽

Congenital Heart ◽

Adult Patients ◽

Cardioverter Defibrillator ◽

Long Term Follow Up

Download Full-text

Long-term Follow-up of the Endoscopic Treatment of Strictures in Pediatric and Adult Patients With Inflammatory Bowel Disease

Journal of Clinical Gastroenterology ◽

10.1097/mcg.0b013e3181354440 ◽

2008 ◽

Vol 42 (8) ◽

pp. 880-885 ◽

Cited By ~ 34

Author(s):

Erina N. Foster ◽

J. Antonio Quiros ◽

Thomas P. Prindiville

Keyword(s):

Inflammatory Bowel Disease ◽

Bowel Disease ◽

Endoscopic Treatment ◽

Adult Patients ◽

Long Term Follow Up ◽

Inflammatory Bowel

Download Full-text

Management of Adult Hydrocephalus With Ventriculoperitoneal Shunts: Long-term Single-Institution Experience

Neurosurgery ◽

10.1227/neu.0b013e31821ffa9e ◽

2011 ◽

Vol 69 (4) ◽

pp. 774-781 ◽

Cited By ~ 54

Author(s):

G Kesava Reddy ◽

Papireddy Bollam ◽

Runhua Shi ◽

Bharat Guthikonda ◽

Anil Nanda

Keyword(s):

Median Time ◽

Adult Patients ◽

Shunt Revision ◽

Shunt Failure ◽

Single Institution ◽

Ventriculoperitoneal Shunts ◽

Shunt Placement ◽

Ventriculoperitoneal Shunting

Abstract BACKGROUND: Ventriculoperitoneal shunting is the most widely used neurosurgical procedure for the management of hydrocephalus. OBJECTIVE: To evaluate our long-term single-institution experience in the management of adult hydrocephalus patients with ventriculoperitoneal shunts. METHODS: Adult patients who underwent ventriculoperitoneal shunt placement for hydrocephalus from October 1990 to October 2009 were included. Medical charts, operative reports, imaging studies, and clinical follow-up evaluations were reviewed and analyzed retrospectively for clinical outcome in adult hydrocephalus patients. RESULTS: A total of 683 adult patients were included in the study. The most common etiologies of hydrocephalus include idiopathic (29%), tumors and cysts (20%), postcraniotomy (13%), and subarachnoid hemorrhage (13%). The overall shunt failure rate was 32%, and the majority (74%) of shunt revisions occurred within the first 6 months. The median time to first shunt revision was 9.31 months. Etiology of hydrocephalus showed a significant impact on the incidence of shunt revision/failure and on the median time to shunt revision. Similarly, the type of hydrocephalus had a significant effect on the incidence of shunt failure and the median time to shunt revision. CONCLUSION: A large proportion of patients (32%) experience shunt failure after shunt placement for hydrocephalus. Although the overall incidence of shunt revision was comparable to previously reported studies, the fact that a large proportion of adult populations with shunt placement experience shunt failure is a concern.

Download Full-text